Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several factual product/composition claims align with the provided label excerpts (Description; Indications; Renal and electrolyte/metabolic precautions). However, multiple clinically important claims (pregnancy use, dosing frequency/individualization, and multiple adverse-effect claims framed as 'commonly reported') are not verifiable because the provided label excerpts do not include the relevant sections (Dosage/Administration, Adverse Reactions, Pregnancy text).
Category Scores
Accurate Statements
Hyzaar is a brand name for a combination blood-pressure medicine containing losartan and hydrochlorothiazide.
11 DESCRIPTION (contains losartan potassium (ARB) + hydrochlorothiazide; indicated for hypertension in 1 INDICATIONS AND USAGE 1.1)
Losartan in Hyzaar is an angiotensin II receptor blocker (ARB).
11 DESCRIPTION (an angiotensin II receptor blocker acting on the AT1 receptor subtype; HYZAAR contains losartan)
Hydrochlorothiazide in Hyzaar is a thiazide diuretic.
11 DESCRIPTION (hydrochlorothiazide described as the diuretic component in the combination tablet)
Hyzaar products are available in fixed-dose combination strengths pairing losartan with hydrochlorothiazide.
11 DESCRIPTION (available for oral administration in tablet combinations of losartan and hydrochlorothiazide; fixed tablet combinations)
Example Hyzaar strengths include 50/12.5 mg and 100/12.5 mg.
11 DESCRIPTION (HYZAAR 50/12.5 and HYZAAR 100/12.5 specified)
People with significant kidney disease may need closer monitoring or alternative therapy with Hyzaar.
5.3 Impaired Renal Function (patients at particular risk; monitor renal function periodically; consider withholding/discontinuing for clinically significant decrease)
People with certain electrolyte imbalances (such as low potassium or low sodium) may need closer monitoring or alternative therapy with Hyzaar.
5.5 Electrolyte and Metabolic Effects (HYZAAR can cause hypokalemia and hyponatremia; monitor serum electrolytes periodically)
People with a history of gout may need closer monitoring or alternative therapy with Hyzaar.
5.5 Electrolyte and Metabolic Effects (hyperuricemia may occur or frank gout may be precipitated with thiazide therapy)
Unsupported Statements
Dosing of Hyzaar is individualized based on blood pressure response and tolerability.
No supporting text for individualized dosing/titration was provided in the included label excerpts (Dosage and Administration section text not provided).
In general, combination ARB/diuretic tablets like Hyzaar are taken once daily for hypertension.
No supporting text for dosing frequency was provided in the included label excerpts (Dosage and Administration section text not provided).
Commonly reported side effects ... can include dizziness or lightheadedness from blood-pressure lowering.
Adverse reaction statements and frequency ('commonly reported') are not present in the provided label excerpts (6 ADVERSE REACTIONS content not provided).
Commonly reported side effects ... can include increased urination early in treatment from the diuretic.
Adverse reaction statements and timing ('early in treatment') are not present in the provided label excerpts (6 ADVERSE REACTIONS content not provided).
Commonly reported side effects ... can include headache.
Adverse reaction statements and frequency ('commonly reported') are not present in the provided label excerpts (6 ADVERSE REACTIONS content not provided).
Hyzaar is typically not used in pregnancy.
Pregnancy section text was not provided in the included excerpts; cannot verify the exact labeled pregnancy use statements.
Hyzaar’s active ingredients (losartan plus hydrochlorothiazide) can sometimes be available as generics or alternative brands.
No label excerpt provided addresses generic availability or alternative brands.
Contradictions
Important Omissions
Boxed warning status/wording (if any).
Importance:
Moderate
Full Dosage and Administration guidance (including dosing frequency, starting doses, titration/individualization, and special instructions).
Importance:
Moderate
Adverse reactions list and any frequency language used in labeling.
Importance:
Moderate
Complete Pregnancy section details (including labeled contraindication/use restrictions and risk statements).
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Non-verifiable claims about dosing frequency/individualization and multiple 'commonly reported' adverse effects could mislead clinical use if they diverge from labeled instructions; pregnancy use claim is not verifiable from provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Several key claims are not verifiable from the provided label excerpts (Dosage/Administration, Adverse Reactions, and Pregnancy text).
Suggested Improvement
Limit claims to those explicitly supported by the provided excerpts; for dosing frequency/individualization, adverse-effect statements, and pregnancy use, cite the exact corresponding label text from Dosage and Administration (2), Adverse Reactions (6), and Pregnancy (8.1) sections.